On October 20, 2025, CMU representatives participated in a DRAP follow-up meeting focused on strengthening pharmacovigilance across public health programmes. The delegation included Sania Nawaz Khan (Pharmacovigilance Officer), Hafiza Ayesha Hameed (Pharmacist – HIV/AIDS, TB & Malaria), Dr. Umair Malik (Treatment Specialist – HIV), Dr. Nazrul Islam (MDR Specialist) and Dr. Ambreen (Program Officer HIV).
The session featured strategic input from WHO Consultant Dr. Jean-Christophe Delumeau and centred on collaborative planning between CMU and DRAP to align systems and processes. Participants discussed practical steps to improve adverse event reporting, data sharing and oversight across HIV, TB, malaria and MDR programmes to reinforce pharmacovigilance capacity at programme level.
With a clear objective to meet WHO GBT Level-3 benchmarks, the meeting emphasised coordinated action, capacity building and standardized procedures to ensure medicine safety and timely risk management. The collaborative approach is intended to strengthen national pharmacovigilance systems and support programme-level implementation across Pakistan’s public health landscape.
